We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
-23.39%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$275M
AUM Growth
-$31.9M
Cap. Flow
+$62.8M
Cap. Flow %
22.81%
Top 10 Hldgs %
72.23%
Holding
42
New
4
Increased
19
Reduced
4
Closed
8

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$28.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.5M
3
BLUE
bluebird bio
BLUE
+$10.5M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$10.3M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$4.17M

Top Sells

Rank Stock Value
1
OMER icon
Omeros
OMER
+$11.3M
2
DYAX
DYAX CORPORATION
DYAX
+$4.36M
3
KITE
Kite Pharma, Inc.
KITE
+$3.65M
4
ANIK icon
Anika Therapeutics
ANIK
+$1.05M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$1.04M

Sector Composition

Rank Sector Weight
1 Healthcare 85.27%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MASI
26
DELISTED
Masimo
MASI
$1.08M 0.39%
25,900
– –
MNKD icon
27
PUT
MannKind Corp
MNKD
$1.22B
$899K 0.33%
+877
New +$5.01K
TMBR
28
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$764K 0.28%
47
+22
+88% +$498K
MDRX
29
DELISTED
Veradigm Inc. Common Stock
MDRX
$634K 0.23%
48,000
– –
NTRA icon
30
Natera
NTRA
$39.4B
$302K 0.11%
31,693
– –
ALPN
31
DELISTED
Alpine Immune Sciences Inc
ALPN
$125K 0.05%
7,500
– –
ADAP
32
DELISTED
Adaptimmune Therapeutics
ADAP
$63K 0.02%
7,691
+636
+9% +$5.2K
NVRO
33
PUT
DELISTED
NEVRO CORP.
NVRO
$36K 0.01%
142
– –
BRK.B icon
34
Berkshire Hathaway Class B
BRK.B
$1.12T
$7K ﹤0.01%
50
– –
ANIK icon
35
Anika Therapeutics
ANIK
$262M
– –
-27,500
Closed -$1.05M
USO icon
36
CALL
United States Oil Fund
USO
$1.81B
– –
-1,731
Closed -$7K
VCYT icon
37
Veracyte
VCYT
$3.73B
– –
-25,000
Closed -$180K
TTOO
38
DELISTED
T2 Biosystems, Inc
TTOO
– –
-4
Closed -$229K
VIVO
39
CALL
DELISTED
Meridian Bioscience Inc
VIVO
– –
-1,252
Closed -$110K
GHDX
40
DELISTED
Genomic Health, Inc.
GHDX
– –
-15,000
Closed -$528K
ELGX
41
DELISTED
Endologix Inc
ELGX
– –
-1,500
Closed -$149K
DYAX
42
DELISTED
DYAX CORPORATION
DYAX
– –
-115,795
Closed -$4.36M
1
2

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

RTW Investments's Q1 2016 Portfolio in Review

As of Q1 2016, RTW Investments held 42 positions worth $275M, down 10% from $307M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

RTW Investments deployed $62.8M of net new capital in Q1 2016, opening 4 new positions and adding to 19 existing holdings. Its largest new stake was Incyte: 379,415 shares worth $27.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Omeros, an estimated $11.3M trimmed.

  • RTW Investments's largest Q1 2016 buy was Incyte: 379,415 shares worth $27.5M.
  • RTW Investments added most to Alnylam Pharmaceuticals in Q1 2016, an estimated $19.5M increase.
  • RTW Investments's biggest Q1 2016 reduction was Omeros, cutting an estimated $11.3M.
  • RTW Investments fully exited DYAX CORPORATION in Q1 2016, selling an estimated $4.36M.
  • RTW Investments's ten largest holdings make up 72% of its $275M portfolio in Q1 2016.
  • RTW Investments opened 4 new positions and closed 8 in Q1 2016.
  • RTW Investments's portfolio value fell 10% quarter-over-quarter to $275M.

Based on RTW Investments's 13F filing for Q1 2016, filed 11 May 2016.